Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.94 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.94 |
| ▸ | GAA | P10253 | 5/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide SCHEMBL14484918 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL2305491 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL3622 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL14401267 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL22594950 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL13114424 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL20598257 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL23064754 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL6361654 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500585-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | Factor Bioscience Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3452081-A1 | COMBINATION THERAPY WITH CPG TLR9 LIGAND | Transgene SA (FR) | 2019-03-13 | — | — | EP | disclosed |
| WO-2018035377-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| CN-107501274-A | It can be used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| EP-3256585-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | Factor Bioscience Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3256156-A1 | IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY | Transgene SA (FR) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017191147-A1 | COMBINATION THERAPY WITH CPG TLR9 LIGAND | TRANSGENE SA (FR) | 2017-11-09 | — | — | WO | disclosed |
| CN-104903325-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| WO-2016128542-A1 | IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY | TRANSGENE SA (FR) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016131052-A1 | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOF | FACTOR BIOSCIENCE INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2014181085-A1 | TUMOUR THERAPY | BAGSHAWE KENNETH DAWSON (GB) | 2014-11-13 | — | — | WO | disclosed |
| CN-101679387-A | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMA | 2010-03-24 | — | — | CN | disclosed |